Navocaftor clinical trials
Also written ABBV-3067.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses navocaftor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses navocaftor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic FibrosisTerminatedPhase 2AbbVieNCT04853368Written as NavocaftorHow we know
- A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222CompletedPhase 2AbbVieNCT03969888Written as ABBV-3067How we know
- A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and NavocaftorCompletedPhase 1AbbVieNCT05538585Written as NavocaftorHow we know
- Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.CompletedPhase 1Galapagos NVNCT03589313Written as GLPG3067 single doseHow we know
- A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.CompletedPhase 1Galapagos NVNCT03128606Written as GLPG3067 single doseHow we know
Given beside what is tested · 1 — navocaftor is usual care or a partner of the new treatment
Codes
What other systems call navocaftor · ClinicalTrials.gg INT018296
- UNII (FDA) W2F2XU189ONAVOCAFTOROne source FDA
- NCI Thesaurus C174930NavocaftorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W2F2XU189O | NAVOCAFTOR | One source FDA |
| NCI Thesaurus | C174930 | Navocaftor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.